CAR T Cell Therapy | CHOP Research Institute

CAR T Cell Therapy

Published on
May 24, 2024
In this week’s news, our researchers have developed the first-of-its-kind bone marrow atlas and innovative, painless wound dressings. Read on to learn more.
Published on
Dec 28, 2023
These six stories received the highest number of engagements on CHOP Research social media channels in 2023.

The purpose of this study is to determine the safety and effectiveness of an experimental form of therapy, known as BEAM-201.

The purpose of this study is to determine the safety and tolerability of an experimental form of therapy, known as UCART22 ("study drug").

Published on
Sep 19, 2022
CHOP physician-scientists discuss their CAR T-cell therapy research for childhood cancers in Where Discovery Leads.

Dr. Weber is developing approaches to enhance CAR-T cell therapies for pediatric cancer by reprogramming T cells with improved durability and exhaustion resistance. His work will uncover molecular mechanisms that promote CAR-T cell exhaustion and identify new targets for therapeutic intervention.

weberew [at]
Published on
Dec 10, 2021
Our research news highlights a study about sequencing bone marrow DNA after CAR T-cell therapy and how it accurately predicts leukemia relapse.
Published on
Jul 8, 2021
The “Pediatric Cancer Dream Team”, co-led by Dr. John Maris, received the Team Science Award from the AACR.

This is an open-label, four-cohort, phase 2 study to determine the efficacy of CART19.

The purpose of this study is to test if the CD19 CAR T cell product tisagenlecleucel  is safe and has beneficial effects in children and young adults who have newly diagnosed high-risk B-cell Acute Lymphoblastic Leukemia that remains MRD-positive after 2 cycles of chemotherapy.